longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Incannex Healthcare

IXHL

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -0.85, above the reasonable range, cheaper than 7.66% of the time in the past 1 years, and the industry ranks 105/257, the industry Median -1.41.

-0.851xP/E
$3.45Stock price
$-4.05Earnings per share
-0.851xP/E
Stock price$3.45Earnings per share$-4.05

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.11x
Typical range
-2.64x–-0.92x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.91x149.86%$59.42B
BAYZFUSBayer Aktiengesellschaft
-27.64x--$55.77B
BAYRYUSBayer
-27.42x--$55.33B
VTRSUSViatris
-47.88x107.75%$19.66B
ELANUSElanco Animal Health
-56.67x129.36%$11.28B
VREOFUSVIREO GROWTH INC
-167.29x--$11.23B
AXSMUSAxsome Therap
-52.87x26.60%$10.13B
CURLFUSCuraleaf Holdings, Inc.
-175.08x--$9.11B
BLTEUSBelite Bio
-66.36x29.87%$6.79B
DFTXUSDefinium Therapeutics
-14.30x53.61%$5.06B
MANEUSVeraDermics
-46.38x97.44%$4.84B
EWTXUSEdgewise Therapeutics
-22.60x137.29%$4.46B
AMLXUSAmylyx Pharmaceuticals
-25.26x1.76%$3.84B
ELVNUSEnliven Therapeutics
-31.88x1.17%$3.38B
TARSUSTarsus Pharmaceuticals
-70.15x34.09%$3.26B
RGCUSRegencell Bioscience
-420.36x--$2.96B
MBXUSMBX Biosciences
-26.73x30.54%$2.79B
GPCRUSStructure Therapeutics
-11.93x102.05%$2.56B
SUPNUSSupernus Pharma
-22.95x70.59%$2.52B
TRLVUSTrulieve Cannabis
-5.10x198.82%$2.41B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.